Psy­che­del­ic biotech ATAI hopes to ex­pand port­fo­lio through re­search part­ner­ship with Mass Gen­er­al

Psy­che­delics have made a come­back for men­tal health re­search, with com­pa­nies like start­up biotech ATAI Life Sci­ences rais­ing mil­lions and earn­ing the back­ing of promi­nent in­vestors like Pe­ter Thiel, but there’s a hole at the heart of the resur­gence: Re­searchers still don’t ful­ly un­der­stand how they work.

A new part­ner­ship be­tween ATAI and world-renowned Mass Gen­er­al Hos­pi­tal hopes to change that.

ATAI is the first part­ner in Mass Gen­er­al’s new Cen­ter for Neu­ro­science of Psy­che­delics, which seeks to ad­vance nov­el men­tal health treat­ments through study­ing the mech­a­nisms that un­der­lie the ther­a­peu­tic ef­fects of psy­che­del­ic agents. The Berlin-based com­pa­ny, found­ed in 2018, fo­cus­es on de­vel­op­ing psy­che­del­ic and non-psy­che­del­ic com­pounds for a va­ri­ety of men­tal health needs.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN